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What is already known about this topic? 
 Pregnancies in women with SCD are at increased risk of stillbirth and birth of 
small for gestational age neonates. 
 Women with HbSS disease have worse perinatal outcome compared to those 
with HbSC disease. 
 
What does this study add? 
 In women with HbSS disease serum PAPP-A at 11-3 weeks’ gestation is 
significantly reduced and this may be an early marker of adverse perinatal 




The data that support the findings of this study are available from the corresponding 








Objective: To assess whether levels of first-trimester pregnancy-associated plasma 
protein A (PAPP-A) differ between women with and without sickle cell disease (SCD). 
 
Methods: Retrospective study of 101 singleton pregnancies in women with SCD 
(including 55 with genotype HbSS, 37 with genotype HbSC and 9 with other 
genotypes). Measured levels of PAPP-A were converted to multiple of the median 
(MoM) values corrected for gestational age and maternal characteristics. Median 
PAPP-A MoM in the SCD group was compared to that of 1010 controls. 
 
Results: In the SCD group median PAPP-A MoM was lower than in the non-SCD group 
(0.72, interquartile range [IQR] 0.54-1.14 versus 1.09, IQR 0.74-1.49; p<0.001). Within 
the SCD group median PAPP-A MoM was lower for those with genotype HbSS than 
HbSC (0.62, IQR 0.44-1.14 versus 0.94, IQR 0.72-1.25; p=0.006). In 7.3% (4/55) of the 
HbSS group there was stillbirth and in these cases PAPP-A was ≤0.5 MoM; in the 
control group the incidence of stillbirth was lower (1%; p<0.001). In HbSS disease the 
incidence of small for gestational age (SGA) neonates was increased. 
 
Conclusion: Pregnancies with HbSS have lower PAPP-A MoM values and higher 






Sickle cell disease (SCD) is the commonest single gene defect in the world.1-3 It is 
defined as an autosomal recessive hemoglobinopathy that includes sickle cell HbSS 
disease and various compound heterozygous genotypes, such as sickle cell HbSC 
disease or sickle cell β-thalassemia (HbSβ-thal) disease, characterized by chronic 
hemolytic anemia and vaso-occlusive complications. A recent systematic review and 
meta-analysis has shown a strong association between SCD and adverse perinatal 
outcomes, including stillbirth and birth of small for gestational age (SGA) neonates.4 
These manifestations could be as a result of abnormal placentation, which may result 
in reduced levels of first trimester pregnancy associated plasma protein-A (PAPP-A). 
However, there are no reported studies that examined the association of SCD and first 
trimester PAPP-A levels. 
 
The objective of this study is to investigate whether serum PAPP-A levels differ in 
pregnancies of women with SCD compared to those in women without SCD and 





The data for this study were derived retrospectively and included all pregnant women 
affected by SCD who attended for combined first-trimester screening for aneuploidies 
(fetal nuchal translucency, serum free ß-HCG and PAPP-A) at St. Thomas’ Hospital, 
London, UK, between 2009 and 2017. Each SCD pregnancy was matched with 10 
non-SCD controls, selected from women of the same racial origin who underwent first-
trimester screening within 10 days of the date of screening of each SCD pregnancy. 
 
 
The inclusion criteria were singleton pregnancy with live fetus at 11-13 weeks’ 
gestation, delivery >20 weeks’ gestation with livebirth or stillbirth and known pregnancy 
outcome. Pregnancies with fetal abnormalities and those ending in induced abortion 
were excluded. Gestational age was determined from the fetal crown-rump length 
(CRL).5 The following characteristics were extracted from maternal records: maternal 
age, weight, height and racial origin (Black, White, Asian), method of conception 
(spontaneous or assisted), cigarette smoking during pregnancy (yes or no), genotype 
of SCD (HbSS, HbSC, HbSß-thal, non-specified SCD).  
 
Serum PAPP-A was measured by an automated devise (Kryptor analytical system, 
Brahms AG, Berlin, Germany) with results being available within 40 min of blood 
collection. The measured levels were converted into multiple of median (MoM) for 
gestational age and corrected for maternal weight, smoking status, racial origin and 
mode of conception.6 Data on PAPP-A levels recorded in MoM were obtained from the 
fetal medicine unit recording system (Astraia Software GmbH, Version 1.24.10, 
Munich, Germany, 2016). Data on pregnancy outcome were obtained from hospital 
records in UK Maternity Patient Data Management, National Maternity Care Record 
System for the NHS (BadgerNet Version 2.9.1.0). 
 
Statistical analysis 
Data were not normally distributed and therefore non-parametric tests were used.  
Characteristics were compared across study groups by the Mann-Whitney U test for 
continuous variables and by the chi-square test for categorical variables. Data are 
presented as median and interquartile range (IQR) or n (%). PAPP-A MoM values for 
SCD pregnancies were compared to the reference group (non-SCD pregnancies), and 
the process repeated for the two main SCD genotypes (HbSS and HbSC). Pregnancy 
outcome (live birth or stillbirth, birthweight and birthweight percentile according to the 
 
 
Fetal Medicine Foundation fetal and neonatal population weight charts7) were 
presented by SCD group.   
 
Analysis was conducted using Stata 15. All tests were two-tailed and P values <0.05 




The genotype of the 101 women with SCD, included 37 cases of HbSC, 55 of HbSS, 3 
of HbCC, 5 of HbSß-thal and 1 of non-specified SCD. There were no significant 
differences in maternal characteristics between the SCD group and controls (Table 1). 
In patients with SCD, compared to controls, the median birth weight in grams and 
centiles was significantly lower (2940 versus 3280 grams; p<0.001 and 17.5 versus 
34.7 centiles respectively.) Stratifying by SCD genotype, median birth weight in grams 
and centiles in pregnancies complicated by HbSC was not significantly different from 
non-SCD pregnancies (median for HbSC 3070; p=0.007 and 23.7 centiles p=0.06). 
Median birth weight in grams and centiles was significantly lower in those with 
genotype HbSS compared to non-SCD pregnancies (median for HbSS 2860 grams; 
p<0.001 and 12 centiles p<0.001).  
 
In the SCD group median PAPP-A MoM was lower than in the non-SCD group (0.72, 
IQR 0.54-1.14 versus 1.09, IQR 0.74-1.49; p<0.001) (Table 2). Within the SCD group 
median PAPP-A MoM was lower for those with genotype HbSS than HbSC (0.62, 0.44-
1.14 versus 0.94; 0.72-1.25; p=0.006). The incidence of PAPP-A ≤0.5 MoM was 
significantly higher in the HbSS group than the controls, but there was no significant 
difference between the HbSC group and controls (Table 3). Similarly, the incidence of 
 
 
stillbirth and birth of SGA neonates was significantly higher in the HbSS group than the 
controls. The four stillbirths in the HbSS group were diagnosed at 20,23, 25 and 29 
weeks’ gestation, respectively; the birthweight was <3rd percentile in three and serum 
PAPP-A was ≤ 0.5 MoM in all four. In the 10 stillbirths of the control group the 




Main findings of the study 
The findings of this study demonstrate that first, in pregnant women with SCD first-
trimester levels of PAPP-A are significantly lower than in non-SCD controls, second, in  
HbSS disease, but not in HbSC disease, median PAPP-A MoM is lower and incidence 
of PAPP-A ≤0.5 MoM is higher than in non-SCD pregnancies, third, in  HbSS disease, 
but not in HbSC disease, the incidence of stillbirth and birth of SGA neonates were 
higher than in non-SCD pregnancies, and fourth, in  HbSS disease, but not in HbSC 
disease, the incidence of PAPP-A ≤0.5 MoM in pregnancies with stillbirths and SGA 
neonates was higher than in non-SCD pregnancies. 
 
Interpretation and implications of the study 
Low first-trimester serum PAPP-A is associated with increased prevalence and severity 
of placental pathology during pregnancy such as stillbirth and fetal growth restriction.8,9 
A recent systematic review and meta-analysis including > 26 000 pregnancies in 
women with SCD showed strong association between SCD and adverse perinatal 
outcome, including 4-fold increased risk of stillbirth and 2.5-fold increased risk of fetal 
growth restriction; women with HbSS disease had significantly worse perinatal 




In SCD there is abnormal placentation and or sickling in the placenta4,10 and the low 
serum PAPP-A may be a reflection of this placental pathology. Pregnancies with HbSS  
disease and low levels of PAPP-A ≤ 0.5 MoM seem to be at highest risk of adverse 
outcome. In this respect, serum PAPP-A could potentially act as a marker of increased 
risk of complications and stimulate the need for closer surveillance and earlier 
therapeutic interventions in this specific group of women. Additionally, in the calculation 
of PAPP-A MoMs in screening for fetal trisomies it may be necessary to adjust for 
maternal SCD, otherwise the associated low PAPP-A would increase the false positive 
rate for trisomies 21, 18 and 13 and lead to unnecessary invasive testing for fetal 
karyotyping.  
 
Strengths and limitations 
This study was conducted at one of the largest referral centers for SCD in the UK, but 
the sample of affected pregnancies is small. Despite this small number we were able to 
demonstrate significant differences between HbSS disease and non-SCD pregnancies 
in serum PAPP-A levels and adverse pregnancy outcome. The incidence of stillbirth in 
the controls (1%) was higher than the national average (04%)11, but this could be 
explained by first, inclusion in this study of stillbirths at ≥ 20 weeks’ gestation, rather 
than ≥ 24 weeks in national statistics, and second inclusion of a highly vulnerable inner 
city Black population. A similar reason may also be true for the observed incidence of 
SGA in the control group (26%), which was higher than the rate of 17% reported in the 
reference range for Black women.7  
 
Conclusion 
In HbSS disease first-trimester serum PAPP-A is decreased and these pregnancies 
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Table 1. Maternal and pregnancy characteristics in SCD and non-SCD control group 
 
Values are given as median (interquartile range) or n (%) 
† Including nine women with other types of SCD 
‡ Available BMI values: all cases in SCD and 821 cases in comparison group 











Gestation at PAPP-A 
analysis (weeks) 
12.6 (12.1-13.0) 12.4 (12.0-12.9) 12.3 (11.7-12.9) 12.4 (12.0-13.3) 
Age  (years) 31.0 (26.8-35.3) 30.5 (26.0-35.4) 30.5 (26.0-35.5) 31.5 (28.1-35.9) 
Body mass index‡ 26 (23-30) 24 (22-27) 23 (21-25) 25 (22-29) 
Racial origin     
       Black 1000 (99.0) 100 (99.0) 55 (100) 37 (100) 
       East Asian 10 (1.0) 1 (1.0) 0 0 
Spontaneous conception § 795 (97.8) 82 (97.6) 44 (100) 30 (93.8) 
Cigarette smoking 46 (4.6) 0 0 0 
Nulliparous  430 (42.6) 43 (42.6) 26 (47.3) 13 (35.1) 
Birthweight percentile 34.7 (8.9-68.5) 17.5 (1.6-45.5) 12.0 (0-41.4) 23.7 (3.3-48.8) 
Birthweight (gm) 3280 (2950-3580) 2940 (2500-3210) 2860 (2400-3140) 3070 (2720-3460) 
Gestation at birth (weeks) 39.9 (38.9-40.7) 38.4 (37.9-39.1) 38.3 (37.7-38.9) 38.6 (38.1-39.9) 
 
 






IQR = interquartile range 
† Including nine women with other types of SCD 
* Mann-Whitney U test, using non-SCD group as comparison group  
Study group Median (IQR) p-value* 
Comparison group (n=1010) 1.09 (0.74-1.49) - 
All SCD (n=101)† 0.72 (0.54-1.14) <0.001 
HbSS (n=55) 0.62 (0.44-1.14) <0.001 
     HbSC (n=37) 0.94 (0.72-1.25) 0.14 
 
 
Table 3. Birth outcomes and proportion of low PAPP-A by study group. 
 
* p values from x2 test, using non-SCD group as comparison group 
† Including nine women with other types of SCD 











 n (%) n (%)  p-value* n (%) p-value* n (%) p-value* 
PAPP-A ≤0.5 MoM 95 (5.0) 24 (23.8) <0.0001 21 (38.2) <0.001 2 (5.4) 0.44 
Stillbirth 10 (1.0) 4 (3.9) 0.01 4 (7.3) <0.001 0 (0) 0.54 
  PAPP-A ≤0.5 MoM 3 (30.0) 4 (100) <0.0001 4 (100) <0.0001 - - 
Small for gestational age‡ 263 (26.0) 43 (42.3) <0.001 24 (43.6) <0.001 14 (37.8) 0.12 
  PAPP-A ≤0.5 MoM 40 (15.2) 14 (32.6) <0.0001 10 (41.7) <0.0001 2 (14.3) 0.65 
